key: cord-0957587-9p07nu6x
authors: Geerts, Hugo; van der Graaf, Piet H.
title: Salvaging CNS Clinical Trials halted due to COVID‐19
date: 2020-05-28
journal: CPT Pharmacometrics Syst Pharmacol
DOI: 10.1002/psp4.12535
sha: 909f0fa6b85dac236694097b706e95921a060fcb
doc_id: 957587
cord_uid: 9p07nu6x

The COVID‐19 pandemic has halted many ongoing CNS clinical trials, especially in Alzheimer’s disease. These long‐duration trials involve many stakeholders, especially the patients and their family members, who have demonstrated their commitment to developing new therapeutic interventions for this devastating disease. We certainly do not want to lose all the knowledge we have gained from these ongoing trials because of the pandemic. While some of these trials will need to restart, others can re‐start at different points along the trial protocol with substantial protocol amendments. However, there is an urgent need to combine useful information from the completers with those subjects undergoing complex protocols deviations and amendments after re‐start. We propose the concept of mechanistic modeling‐based virtual twin patients as a possible solution to harmonize the readouts from these complex and fragmented clinical datasets in a biologically relevant way.

The COVID-19 pandemic has halted many ongoing CNS clinical trials, especially in Alzheimer's disease. These long-duration trials involve many stakeholders, especially the patients and their family members, who have demonstrated their commitment to developing new therapeutic interventions for this devastating disease. We certainly do not want to lose all the knowledge we have gained from these ongoing trials because of the pandemic.

While some of these trials will need to restart, others can re-start at different points along the trial protocol with substantial protocol amendments. However, there is an urgent need to combine useful information from the completers with those subjects undergoing complex protocols deviations and amendments after re-start. We propose the concept of mechanistic modeling-based virtual twin patients as a possible solution to harmonize the readouts from these complex and fragmented clinical datasets in a biologically relevant way.

A majority of ongoing clinical trials has been affected by the COVID-19 pandemic and trials in Neurodegenerative Diseases are no exception. To that end, the US Food and Drug Administration (FDA) recently published guidance stating, "FDA recognizes that protocol modifications may be required, and that there may be unavoidable protocol deviations due to COVID-19 illness and/or COVID-19 control measures. The necessity for, and impact of, COVID-19 control measures on trials will vary depending on many factors, including the nature of disease under study, the trial design, and in what region(s) the study is being conducted (ref 2 These events will very likely lead to unprecedented issues of 'missingness' in the datasets, far beyond anything we have seen before and not yet considered in this FDA guidance. At the time of trial pause, there will be three patient categories: those who have completed the trial, those who started but had their trial was interrupted, and those who enrolled but have not yet started. Some protocol deviations for the patients currently in the trial include involuntary drug holiday (especially

This article is protected by copyright. All rights reserved with iv formulations), change in medications (anxiolytics, antidepressants) for addressing mental health issues and missing site visits that can be partially mitigated by remote monitoring. Of particular concern are the involuntary drug holidays because the underlying pathological mechanism that was targeted with the drug, picks up again and the patient faces a completely new pathological environment when the drug trial is restarted. Also, when considering an 18 month Phase III study enrolling about 600 patients/year for an anticipated enrollment of 1800 patients, up to 60% of subjects in the trial can face substantial disruptions.

There will be also subjects from the last two groups that will not return to the trial once it restarts. These factors are exacerbated for patients with neurodegenerative diseases due to their age, fragility, co-morbidity, co-medication and other factors. Unfortunately, we will likely lose a sizeable cohort of trial participants due to death from COVID-19, even those that had almost completed their trial.

As we cannot afford to lose the investment by many stakeholders, not in the least the patients and their family members, it is imperative that we explore all possible avenues to generate as much knowledge as possible from these incomplete datasets. Traditional statistical methods such as Last Observation Carried Forward for accounting for missing data will likely be inadequate for such complex and fragmented databases. With regard to Machine Learning, the number of completers in a trial for a "training" set is insufficient to warrant a substantial generalization to other trial participants.

In this paper, we propose a computational modeling approach that combines limited clinical data with underlying biological principles to generate predictions at the individual patient level.

This article is protected by copyright. All rights reserved This mechanism-based QSP approach has been successfully used in blindly predicting an unexpected Phase I scopolamine challenge study in healthy volunteers with a drug affecting a new yet untested target 5 . Moreover, the modeling platform has generated testable hypotheses on the cognitive worsening of BACE inhibitors 6 So far, many biological assumptions in these models have been extensively tested and calibrated with clinical trials, based on group average data. However, applications have included the development of a classifier to predict the complex pharmacodynamical interactions on extrapyramidal motor symptoms in a real-world dataset in individual schizophrenia patients on two antipsychotics 9 in the absence of a training set and with a 35% better performance than the state-of-the-art calculations.

The model will be validated using the actual fragmented dataset of the trial. In a first step, a virtual twin population from the 'completers' database can be generated with the same properties as the observed population, starting from baseline data. The QSP model will then generate a fully blinded set of expected clinical outcomes at the individual patient level based on the trial protocol, which can be compared to the real outcomes. A second level of validation would include prediction of the intermediate outcomes from patients who had reached specific time-points before their trial has been interrupted. A third important level is the prediction of the clinical trajectory of those patients that have restarted with the many protocol amendments to ensure generalizability to these subjects.

Once these validation are performed satisfactorily with a pre-defined similarity criterion, this method can be applied to predict clinical progression of the patients that have not yet completed the trial by estimating how dropouts, protocol amendments and deviations after the trial restart would have affected the clinical trajectory, with the ultimate goal of interpolating the functional trajectory back to the original trial design (see Fig 1) . In principle, this would allow to 'pool' these newly Accepted Article generated data with the data from the completers, resulting in sufficient number of subjects for 'bona fide' statistical analysis and conclusions about the trial outcome.

In these validation steps, modifications such as coupling factors linking -amyloid levels to impact on glutamatergic or nicotinic neurotransmission or the impact of benzodiazepines on GABA receptors can be modified within biologically relevant ranges. With over 35 CNS targets in the model, including amyloid and tau pathological processes, the Virtual Twin platform can cover a large range of clinical trial conditions in AD and PD.

Regulatory agencies are increasingly exposed to QSP approaches in submission 10 . However, most of the experience has been in early clinical development and QSP has played a supportive rather than a pivotal role, complementing a larger evidentiary package. Therefore, the question what would constitute a qualified (let alone validated) Virtual Twin QSP model from a regulatory perspective remains to be defined by key stakeholders.

The three levels of validation, as mentioned above would generate predictions of almost the same number of subjects from the fragmented dataset as in the original design, therefore this number will likely be sufficient to "interpolate" the clinical trajectory to the original plan.

This report proposes to explore the combination of PBPK and QSP as a possible innovative way to correct the many substantial changes in the interrupted clinical trials with the purpose to 'generate' the functional trajectory back to the original protocol design. We acknowledge that this has never been proposed before, but it is one of the possible approaches to salvage the information gathered so far at substantial costs. 

This article is protected by copyright. All rights reserved distribution of good responders, non-responders and subjects worsening over time. Ideally, pooling data from different sponsors might be another solution to cover a large range of targets and conditions. It has to be emphasized that the validation at the three different levels, will be performed by prospectively predicting the functional outcome solely based on the baseline characteristics but without knowledge of the outcome.

There are a number of limitations to this approach. The current version of the platform does not cover all possible therapeutic interventions in AD and PD; therefore a number of targets currently being tested in the clinic are beyond the scope of the model. There might be other genotypes that drive the clinical outcome beyond the three implemented here, for instance the BDNFVal66Met genotype. Although baseline biomarkers of amyloid, tau load status and brain atrophy provide us with a fairly good estimate of the pathology, only in those cases where we have sequential biomarker readouts can we estimate the individual rate of pathology progression.

Another major limitation of this approach is the unknown central effects of the SARS-CoV-2 virus for those patients who become infected; possibly interfering with the disease pathology or impacting the functional cognitive readout. However, in that case lack of validation could indicate a major impact of this pathology. Accordingly, an extensive sensitivity analysis of the platform can possibly identify the impact of the SARS-CoV-2 virus on neuronal functioning.

In summary, Virtual Twin using PBPK/ QSP can enable the extrapolation and "bridging" of the clinical trajectory for the many patients unable to complete the trial, helping to salvage the information gathered at substantial human and investment cost for the research participants, their family members, health care professionals and sponsors. The model is individualized, so it can account for many different possibilities, including unforced drug holiday and change of medications at the individual patient level. When the trial restarts (likely with a new protocol), the approach can bridge the before and after to hopefully salvage the data and communicate continuity of information with scientists and regulators.

This article is protected by copyright. All rights reserved Legend to Figure 1 .

pandemic. A virtual twin population is created with the same characteristics as the observed population of completers (blue bars). Using those data, the QSP model generates expected clinical outcomes, which can be compared to the real outcomes of this responder population. The model takes into account pharmacokinetic and pharmacodynamical interactions between the investigative drug and co-medications, genotypes and disease states. Once this validation is performed satisfactorily, the QSP model can be applied to predict clinical progression of the non-completer patient population (green bars) that have dropped out. The model can also 'correct' for protocol amendments when the trial re-starts, allowing to pool these results with the completer results. In this way valuable information can be salvaged.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation

Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram

COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET

5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [(11)C]SB207145 PET in humans

Tracey Rapp1, Phil Iredale1, Carolyn Rowinski1, Robert Carr2, Patrick Roberts2, Athan Spiros2, Hugo Geerts2 Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using